US FDA exams azithromycin study deaths
This article was originally published in Scrip
Executive Summary
On the same day a newly published study reported that patients taking azithromycin, sold by Pfizer under the brand name Zithromax, had an increased risk of sudden death, particularly those caused by adverse cardiovascular events, compared with other antibiotics, the US FDA said it was opening a probe to examine the results.